Back to News
Market Impact: 0.05
Nicox Announces NCX 470 NDA in China Accepted for Review
Source: GlobeNewswire
Healthcare & BiotechRegulation & Legislation
The article defines a PDUFA date as the FDA's target deadline to complete review and issue a decision on a New Drug Application under the Prescription Drug User Fee Act. It contains no company-specific drug, decision, financial magnitude, or market-moving update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- US legislators push AI safety laws amid human extinction warnings
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)